The stock of Regulus Therapeutics Inc (NASDAQ:RGLS) is a huge mover today! About 279,149 shares traded hands. Regulus Therapeutics Inc (NASDAQ:RGLS) has declined 61.48% since April 21, 2016 and is downtrending. It has underperformed by 66.81% the S&P500.
The move comes after 6 months positive chart setup for the $129.66 million company. It was reported on Nov, 23 by Barchart.com. We have $2.68 PT which if reached, will make NASDAQ:RGLS worth $3.89M more.
Analysts await Regulus Therapeutics Inc (NASDAQ:RGLS) to report earnings on February, 27. They expect $-0.36 EPS, down 157.14% or $0.22 from last year’s $-0.14 per share. After $-0.37 actual EPS reported by Regulus Therapeutics Inc for the previous quarter, Wall Street now forecasts -2.70% EPS growth.
Regulus Therapeutics Inc (NASDAQ:RGLS) Ratings Coverage
Out of 5 analysts covering Regulus Therapeutics (NASDAQ:RGLS), 4 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 80% are positive. Regulus Therapeutics has been the topic of 10 analyst reports since August 5, 2015 according to StockzIntelligence Inc. The rating was downgraded by BMO Capital Markets on Tuesday, June 28 to “Market Perform”. The rating was maintained by Chardan Capital Markets with “Buy” on Tuesday, June 28. The stock of Regulus Therapeutics Inc (NASDAQ:RGLS) earned “Buy” rating by Chardan Capital Markets on Tuesday, June 7. The firm has “Buy” rating by Chardan Capital Markets given on Wednesday, April 13. The firm has “Outperform” rating by Wells Fargo given on Friday, December 4. BMO Capital Markets initiated it with “Outperform” rating and $16 target price in Tuesday, April 12 report. The stock of Regulus Therapeutics Inc (NASDAQ:RGLS) has “Buy” rating given on Tuesday, June 28 by Needham. As per Wednesday, August 5, the company rating was maintained by Wedbush. The firm has “Buy” rating by Needham given on Wednesday, November 2.
According to Zacks Investment Research, “Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs, called microRNA therapeutics. The Company’s products aim to treat or prevent hepatitis C infections, cardiovascular disease, fibrosis, oncology, immuno-inflammatory diseases, and metabolic diseases. Regulus Therapeutics Inc. is based in La Jolla, California.”
Insitutional Activity: The institutional sentiment decreased to 1.2 in 2016 Q2. Its down 0.03, from 1.23 in 2016Q1. The ratio worsened, as 26 funds sold all Regulus Therapeutics Inc shares owned while 14 reduced positions. 6 funds bought stakes while 43 increased positions. They now own 27.05 million shares or 18.99% less from 33.39 million shares in 2016Q1.
Wellington Mgmt Group Llp accumulated 4.89 million shares or 0% of the stock. Alliancebernstein L P holds 0% of its portfolio in Regulus Therapeutics Inc (NASDAQ:RGLS) for 47,100 shares. Morgan Stanley has 0% invested in the company for 28,009 shares. Brown Advisory has 0% invested in the company for 34,500 shares. Blackrock Fund reported 1.68M shares or 0% of all its holdings. Voya Invest Ltd Liability reported 18,011 shares or 0% of all its holdings. Metropolitan Life Com has 0% invested in the company for 32,051 shares. California State Teachers Retirement Systems accumulated 0% or 81,343 shares. Swiss National Bank reported 58,200 shares or 0% of all its holdings. Zurcher Kantonalbank (Zurich Cantonalbank) owns 1,123 shares or 0% of their US portfolio. Moreover, Amici Capital Limited Liability Company has 0.04% invested in Regulus Therapeutics Inc (NASDAQ:RGLS) for 82,500 shares. Bourgeon Management Ltd Liability accumulated 0.13% or 70,704 shares. Mufg Americas Corp has invested 0% of its portfolio in Regulus Therapeutics Inc (NASDAQ:RGLS). Moreover, Teachers Retirement Systems Of The State Of Kentucky has 0% invested in Regulus Therapeutics Inc (NASDAQ:RGLS) for 108,900 shares. Geode Mgmt Ltd Com has 199,054 shares for 0% of their US portfolio.
More recent Regulus Therapeutics Inc (NASDAQ:RGLS) news were published by: Fool.com which released: “Regulus Therapeutics Inc. Clinical Hold: Should Investors Be Yellow-Bellied?” on June 28, 2016. Also Fool.com published the news titled: “Why Regulus Therapeutics Inc. Fell 20.1% in April” on May 10, 2016. Marketwatch.com‘s news article titled: “Regulus Therapeutics’ stock set to fall after FDA places hepatitis C treatment …” with publication date: June 27, 2016 was also an interesting one.
RGLS Company Profile
Regulus Therapeutics Inc., incorporated on September 5, 2007, is a biopharmaceutical firm focused on discovering and developing drugs that target microribonucleic acid (microRNAs) to treat a range of diseases. The Firm uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state. The Company’s Regulus microMarkers division is focused on identifying microRNAs as biomarkers of human disease. It has a research collaboration with Biogen focused on the discovery of microRNAs as biomarkers for multiple sclerosis and has completed research for another pharmaceutical firm to explore microRNAs as biomarkers for specific patient populations.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.